Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion of 12-week follow up anticipated by year end with data shortly thereafter SSRI drug interaction study initiated MHRA approval for new SPL026 trial LONDON, Oct. 14, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “…


Previous articleRevive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
Next articlePT365 – Dr. Jennifer Montjoy – KAP: Self-Agency Through Intention, Titration, and Ceremony